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INTRODUCTION
 ■ An estimated 2.7 to 3.9 million Americans suffer from chronic HCV infection.1 The 
primary goal of therapy in chronic HCV infection is eradication of HCV RNA, which 
is predicted by achievement of SVR12. Current treatment guidelines recommend 
treatment with antiviral medications for all patients with chronic HCV infection.2 
Harvoni® (ledipasvir/sofosbuvir) is a combination of DAA agents FDA-approved  
for the treatment of HCV genotypes 1, 4, 5, and 6 on October 10, 2014.3
 ■ Real-world studies of LDV/SOF in the VA system and in academic and community 
medical centers have shown rates of SVR12 over 90% with 8-week, 12-week, and  
24-week courses with and without ribavirin.4-7 There is an unmet need for real-world 
effectiveness data in the Medicaid population.
 ■ HCV genotype 1 accounts for 74% of chronic HCV infections in the US.8 Several 
durations of treatment with LDV/SOF are FDA-approved, and selection of a treatment 
regimen is based on clinical factors of the patient’s HCV infection, including treatment 
history, cirrhosis, and baseline HCV RNA.2,3
 ■ The Massachusetts Medicaid (MassHealth) DUR program maintains a comprehensive 
HCV medication management program. The MassHealth PA criteria allow for optimized 
treatment of chronic HCV infection and do not contain restrictions  
based on liver fibrosis stage, SUD, or prescriber specialty.
OBJECTIVES
 ■ Primary Objective: To evaluate the effectiveness of HCV genotype 1 treatment with 
LDV/SOF as measured by SVR12 in the MassHealth FFS and PCC plan population
 ■ Secondary Objectives: To evaluate the effectiveness of HCV genotype 1 treatment 
with LDV/SOF within the subgroups of 8, 12, and 24-week regimens, and to identify 
predictors of treatment failure
METHODS
 ■ This retrospective cohort study utilized clinical and demographic data that is routinely 
compiled from PA requests by the comprehensive HCV medication management 
program of the MassHealth DUR program in an internal database, as well as 
pharmacy claims data from the MassHealth POPS.
 ■ Inclusion Criteria:
 – Member is over 18 years of age
 – Diagnosis of HCV genotype 1
 – Completion of at least one 8-week, 12-week, or 24-week course of LDV/SOF with 
or without ribavirin between October 10, 2014 and November 1, 2016
 – Availability of SVR12 result or detectable viral load any time after treatment 
completion prior to November 1, 2016
 – Continuous MassHealth FFS or PCC coverage for a minimum of the duration of 
treatment with LDV/SOF
 ■ Exclusion Criteria:
 – Mixed HCV genotype
 – HCV genotype other than genotype 1
 ■ Study Variables:
 – Viral load data was collected from the internal database of the comprehensive 
HCV medication management program.
 – Other clinical variables included HIV co-infection, SUD, cirrhosis, history of failure 
on a previous HCV treatment, history of failure on a previous DAA agent, baseline 
HCV RNA ≥6 million IU/mL, and presence of potential drug-drug interaction with 
LDV/SOF.
 – A member was considered to have a potential drug-drug interaction if there was at 
least one paid claim for a medication that may affect concentrations of LDV/SOF at 
any point during the member’s treatment with LDV/SOF.
 – Demographic variables included sex and age.
 ■ Statistical Analysis:
 – Primary Objective:
 › Viral load data was used to calculate the proportion of all members who 
completed at least one 8-week, 12-week, or 24-week course of LDV/SOF  
and achieved SVR12.
 – Secondary Objectives:
 › Viral load data was used to calculate the proportion of members who achieved 
SVR12 by treatment regimen and by clinical  and demographic variables for each 
treatment regimen.
 › The number of members with and without each clinical and demographic 
variable who achieved SVR12 and who did not achieve SVR12 were used to 
perform bivariate and multivariate analyses and calculate the odds of failure to 
achieve SVR12.
DISCUSSION
 ■ The proportion of members who achieved SVR12 overall is comparable to the 
proportions of members who achieved SVR12 in other real-world studies of LDV/SOF 
(Table 2).4-7
 ■ LDV/SOF is FDA-approved as an 8-week regimen in treatment-naïve, non-cirrhotic 
members with a baseline HCV RNA <6 million IU/mL.3 Current treatment guidelines 
note that preliminary real-world data for the comparative effectiveness of 8-week 
and 12-week regimens in this population is inconclusive, and leave the selection of 
treatment duration to the discretion of the prescriber.2 
 ■ A high proportion of treatment-naïve, non-cirrhotic, HCV mono-infected members  
with a baseline HCV RNA <6 million IU/mL that received 8 weeks of LDV/SOF achieved 
SVR12. These results are comparable to those seen with 8-week regimens in other 
real-world studies of LDV/SOF (Table 2).4-7 
 ■ The proportion of members who received 12 weeks of LDV/SOF with ribavirin and 
achieved SVR12 is comparable to the proportion of members who received 24 weeks 
of LDV/SOF and achieved SVR12 (Table 2).
 ■ Bivariate and multivariate analyses revealed no statistically significant differences 
in odds of failure to achieve SVR12 by clinical and demographic variables, with the 
exception of lower odds of failure with cirrhosis in members receiving 24 weeks of 
treatment.
LIMITATIONS
 ■ Members for whom viral load data is not available or who had an undetectable viral 
load less than 12 weeks after treatment completion were not included (N=228).  
These members may account for additional cure rate data.
 ■ Pharmacy claims data was only available for claims billed to a MassHealth FFS or  
PCC plan. Medications billed to other payers or paid in cash are not included, and  
may account for additional drug-drug interactions.
 ■ Data regarding history of failure on a previous HCV treatment or DAA agent were 
compiled from the internal database of the MassHealth comprehensive HCV medication 
management program, and included discontinuation of prior therapies because of 
adverse events, as well as relapse after completion of a full treatment course.
CONCLUSION
 ■ Treatment of HCV genotype 1 with LDV/SOF is associated with a high rate of SVR12  
in one state’s Medicaid population, including treatment with 8 weeks of LDV/SOF in 
non-cirrhotic, HCV mono-infected members with a baseline HCV RNA <6 million IU/mL.
 ■ The clinical and demographic variables included in this study were not found to be 
predictors of treatment failure, as they were not associated with statistically significant 
differences in odds of failure to achieve SVR12. However, cirrhosis was associated with 
lower odds of failure to achieve SVR12 in members receiving 24 weeks of LDV/SOF.
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ABBREVIATIONS
CI = confidence interval, DAA = direct-acting antiviral, DUR = drug utilization review, 
FDA = Food and Drug Administration, FFS = Fee-For-Service,  HCV = hepatitis C virus, 
HIV = human immunodeficiency virus, IU = international units,  
LDV/SOF = ledipasvir/sofosbuvir, OR = odds ratio, PA = prior authorization,  
PCC = Primary Care Clinician, POPS = Pharmacy Online Processing System,  
RNA = ribonucleic acid, SUD = substance use disorder,   
SVR12 = sustained virologic response at 12 weeks, VA = Veterans Affairs
Table 1. Proportions of Members by Clinical and Demographic Variables, N (%)
Characteristic
LDV/SOF for  
8 weeks
N=297
LDV/SOF for 12 weeks  
with ribavirin
N=69
LDV/SOF for 12 weeks 
without ribavirin
N=399
LDV/SOF for 24 weeks  
with or without ribavirin
N=31




Male 163 (54.9%) 55 (79.7%) 258 (64.7%) 18 (58.1%) 494 (62.0%)
Female 134 (45.1%) 14 (20.3%) 141 (35.3%) 13 (41.9%) 302 (38.0%)
Age
Mean age, in years (SD) 49.8 (11.0) 57.4 (5.6) 54.5 (8.9) 57.4 (7.7) 53.1 (9.9)
<65 years 291 (98.0%) 67 (97.1%) 380 (95.2%) 27 (87.1%) 765 (96.1%)
≥65 years <11 (2.0%)* <11 (2.9%)* 19 (4.8%) <11 (12.9%)* 31 (3.9%)
Comorbidities
HIV 0 (0.0%) 10 (14.5%) 128 (32.1%) <11 (12.9%)* 142 (17.8%)
SUD 53 (17.9%) <11 (13.0%)* 50 (12.5%) <11 (3.2%)* 113 (14.2%)
Cirrhosis 0 (0.0%) 41 (59.4%) 177 (44.4%) 23 (74.2%) 241 (30.3%)
Treatment History
Treatment-naïve 297 (100.0%) 19 (27.5%) 311 (77.9%) <11 (6.5%)* 629 (79.0%)
Treatment-experienced, total 0 (0.0%) 49 (71.0%) 88 (22.1%) 29 (93.6%) 166 (20.9%)
Treatment-experienced, DAA 0 (0.0%) <11 (4.4%)* <11 (0.5%)* <11 (22.6%)* 12 (1.5%)
Other
Baseline HCV RNA ≥6 million IU/mL 0 (0.0%) <11 (10.1%)* 130 (32.6%) <11 (12.9%)* 141 (17.7%)
Baseline HCV RNA <6 million IU/mL 297 (100.0%) 62 (89.9%) 268 (67.2%) 26 (83.9%) 653 (82.0%)
DDI 13 (4.4%) <11 (11.6%)* 27 (6.8%) <11 (25.8%)* 56 (7.0%)
DAA=direct-acting antiviral, DDI=drug-drug interaction based on claims history, HCV=hepatitis C virus, HIV=human immunodeficiency virus, IU=international units, LDV/SOF=ledipasvir/sofosbuvir, SD=standard deviation, SUD=substance use disorder, RNA=ribonucleic acid
*Not reportable due to cell size <11
Table 2. Proportions of Members Who Achieved SVR12, N(%)
Characteristic
LDV/SOF for  
8 weeks
N=297
LDV/SOF for 12 weeks  
with ribavirin
N=69
LDV/SOF for 12 weeks 
without ribavirin
N=399
LDV/SOF for 24 weeks  
with or without ribavirin
N=31
LDV/SOF total for  
all members
N=796
Total 285 (96.0%) 62 (89.9%) 382 (95.7%) 27 (87.1%) 756 (95.0%)
Sex
Male 155 (95.1%) 49 (89.1%) 249 (96.5%) 16 (88.9%) 469 (94.9%)
Female 130 (97.0%) 13 (92.9%) 133 (94.3%) 11 (84.6%) 287 (95.0%)
Age
<65 years 279 (95.9%) 61 (91.0%) 364 (95.8%) 23 (85.2%) 727 (95.0%)
≥65 years <11 (100.0%)* <11 (50.0%)* 18 (94.7%) <11 (100.0%)* 29 (93.6%)
Comorbidities
HIV 0 (N/A) <11 (90.0%)* 124 (96.9%) <11 (75.0%)* 136 (95.8%)
SUD 51 (96.2%) <11 (100.0%)* 46 (92.0%) <11 (100.0%)* 107 (94.7%)
Cirrhosis 0 (N/A) 36 (87.8%)  168 (94.9%) 22 (95.7%) 226 (93.8%)
Treatment History
Treatment-naïve 285 (96.0%) 17 (89.5%) 298 (95.8%) 0 (0.0%) 600 (95.4%)
Treatment-experienced, total 0 (N/A) 45 (90.0%) 84 (95.5%) 27 (93.1%) 156 (93.4%)
Treatment-experienced, DAA 0 (N/A) <11 (100.0%)* <11 (100.0%)* <11 (85.7%)* 11 (91.7%)
Other
Baseline HCV RNA ≥6 million IU/mL 0 (N/A) <11 (100%)* 126 (96.9%) <11 (100.0%)* 137 (97.2%)
Baseline HCV RNA <6 million IU/mL 285 (96.0%)  55 (88.7%) 256 (95.5%) 22 (84.6%) 618 (94.6%)
DDI 12 (92.3%) <11 (100%)* 24 (88.9%) <11 (87.5%)* 51 (91.1%)
DAA=direct-acting antiviral, DDI=drug-drug interaction based on claims history, HCV=hepatitis C virus, HIV=human immunodeficiency virus, IU=international units, LDV/SOF=ledipasvir/sofosbuvir, N/A=not applicable, SD=standard deviation, SUD=substance use disorder, RNA=ribonucleic acid
*Not reportable due to cell size <11
RESULTS
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